Business
Here’s how much weight loss drugs could cost you under Trump’s deals with Eli Lilly, Novo Nordisk
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025.
Shelby Knowles | Bloomberg | Getty Images
President Donald Trump on Thursday struck landmark deals with Eli Lilly and Novo Nordisk to slash the prices of their blockbuster weight loss drugs.
Under the agreements, the monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350 starting next year, depending on the dosage and insurance coverage a patient has, Trump administration officials said.
Existing GLP-1s, including Eli Lilly’s obesity injection Zepbound and Novo Nordisk’s competitor Wegovy, carry list prices above $1,000 a month, which has prevented many patients from taking them. Both companies have introduced lower cost options for people paying in cash and purchasing the drugs directly through their websites.
But the deals with Trump, as part of his “most favored nation” policy, take those efforts to expand access even further. Here’s how much weight loss drugs could cost for patients under the new agreements, based on the details shared so far.
Medicare
Medicare has covered GLP-1 drugs for diabetes and some other medical conditions: for example, Wegovy for slashing cardiovascular risks. But under the new deals, Medicare will start covering the drugs for obesity for the first time starting in mid-2026, which could allow more seniors to qualify for them and spur more private insurers to cover them.
Certain Medicare patients will pay a copay of $50 per month for all approved uses of GLP-1 drugs, including diabetes and obesity treatment.
But the Trump administration is putting some constraints on which Medicare beneficiaries will be eligible to receive GLP-1s for obesity and cardiovascular and metabolic benefits.
Patients are eligible if they fall into these three cohorts:
- The first includes those who are overweight — with a body mass index greater than 27 — or with prediabetes or established cardiovascular disease.
- The second group is people with obesity – with a BMI greater than 30 – and uncontrolled hypertension, kidney disease or heart failure.
- The third group is patients with severe obesity, or anyone with a BMI greater than 35.
Eli Lilly and Novo Nordisk voluntarily agreed to reduce the prices the government pays for existing GLP-1 drugs already approved for diabetes and other uses to $245 a month, across all non-starting doses. Savings generated by those price reductions will allow Medicare to start paying that same price point for GLP-1s for patients with obesity and a high metabolic or cardiovascular risk.
Direct-to-consumer
The agreement will also allow patients to get GLP-1s on direct-to-consumer platforms at steeper discounts than they already receive through drugmakers’ existing sites.
On TrumpRx – the government’s direct-to-consumer platform for buying prescription drugs with cash expected to launch next year – the average monthly cost for Wegovy, Zepbound and other injectable GLP-1s will start at $350 and drop to $250 within the next two years, according to senior administration officials.
Starting doses of upcoming obesity pills from Eli Lilly and Novo Nordisk, pending approvals, will be $149 per month on TrumpRx, Medicare and Medicaid. Under the deals announced Thursday, Eli Lilly will get fast-track reviews of its forthcoming pill.
Eli Lilly on Thursday said it would lower prices by $50 on its own direct-to-consumer platform, LillyDirect, which already offers Zepbound and other drugs at a discount to cash-paying patients. The multidose pen of Zepbound will be available for $299 per month at the lowest dose, with additional doses being priced up to $449 per month.
Eli Lilly’s pill, once approved, will be available at the lowest dose starting at $149 per month
Medicaid
State Medicaid coverage of GLP-1 drugs for obesity is spotty.
But Novo Nordisk and Eli Lilly agreed to extend lower government pricing for their GLP-1 drugs – $245 per month across all other non-starting doses – to all 50 Medicaid programs for all covered uses.
States will have to opt into those prices, meaning some may not. Check with your state government about coverage.
Business
Trump Might Welcome Chinese Investment, but America Is Wary
A hallmark of President Trump’s second term has been his penchant for negotiating economic deals with countries that pledge to invest trillions of dollars in the United States
“It’s now pouring in from all parts of the world,” Mr. Trump said during a speech last fall in which he boasted of nearly $20 trillion of foreign investment.
The meetings this week between Mr. Trump and China’s leader, Xi Jinping, in Beijing are expected to include talks over purchases of American farm products and planes and the possibility of expanding access for American companies into China’s vast consumer market.
There has also been speculation that Mr. Trump and his advisers are seeking a major investment from China. But such a pledge could be complicated by deep distrust in the United States toward Chinese firms, which many workers blame for the hollowing out of American manufacturing.
Treasury Secretary Scott Bessent acknowledged the challenge in an interview on CNBC on Thursday, explaining that the United States and China were working to develop an investment board that would determine what sectors were acceptable for Chinese investment. That would essentially provide China with guidance on how to invest in the United States without its transactions being blocked by the Committee on Foreign Investment, an interagency group that reviews foreign investment and is led by Mr. Bessent.
“Look, there are plenty of things that the Chinese could invest in in the U.S.,” said Mr. Bessent, who is in Beijing with Mr. Trump.
Chinese investment in the United States has declined sharply in recent years amid tougher investment screening standards nationally and at the state level.
That sentiment could ultimately clash with Mr. Trump’s transactional instincts and his desire to return home with a big-ticket win.
“If Trump were to be committed to a major investment deal with China, there’s still a challenge of implementation,” said Kyle Jaros, an expert on U.S.-China ties at the University of Notre Dame. “It would take real follow-through to overcome a lot of the political and regulatory barriers that are in place right now.”
According to a report published last month by the research firm Rhodium Group, less than $3 billion of Chinese investment in the United States was announced in 2025. That was the lowest on record, with investment peaking at around $45 billion in 2016.
The United States has imposed tight restrictions on Chinese investment out of national security concerns, making it difficult for Chinese firms to build factories near military facilities. Some states also have enacted restrictions on Chinese purchases of real estate and farmland.
China’s clean energy technology, such as electric vehicles and batteries, has also faced challenges in the United States because of political backlash. There was a surge of Chinese investment in those sectors after clean energy and tax legislation was passed under the Biden administration in 2022, but according to Rhodium, more than half of those investments have been canceled, paused or delayed.
A $2.4 billion electric vehicle battery factory that the Chinese company Gotion was building in Michigan was canceled last year after the community there protested and mounted legal challenges to stop the project.
Other types of Chinese investment have also stirred controversy. That includes the recent purchase by Nongfu Spring, a Chinese bottled water company, of a warehouse in New Hampshire that it wants to turn into a bottling facility. The purchase was reviewed last year by the state’s attorney general.
After the inquiry found that there was no wrongdoing associated with the transaction, Gov. Kelly Ayotte of New Hampshire issued executive orders to block China, Russia and Iran from getting access to data or purchasing land or property in the state. “Foreign adversaries like China should not be doing business in New Hampshire,” said Ms. Ayotte, a Republican.
There continues to be deep skepticism within the U.S. automobile industry about competition from China. Last month, a group of American steel associations sent a letter to top Trump administration officials urging them to keep Chinese car manufacturers out of the United States.
“As representatives of our nation’s manufacturing sector, we urge you to ensure American competitiveness by not surrendering access to the U.S. auto market to the Chinese Communist Party,” they wrote. “Additionally, allowing Chinese companies and Chinese autos into the U.S. would create consequential, unacceptable national security risks.”
Agriculture also remains a contentious issue. The chairman of the House select committee on China, Representative John Moolenaar, a Republican from Michigan, introduced new legislation this month that would ban China from acquiring U.S. farmland.
“Food security is national security, and we cannot allow foreign adversaries like China to buy up American farmland near our most sensitive military and critical infrastructure sites,” Mr. Moolenaar said.
The bipartisan bill would create a requirement for the federal government to review Chinese deals involving ports and telecommunications infrastructure. It would also apply to purchases made by investors from Russia, Iran and North Korea
Michael Pillsbury, a China scholar who has served as an outside adviser to the Trump administration, said that the president’s advisers were concerned about Chinese investments in sensitive sectors such as semiconductors, artificial intelligence, biotechnology, aerospace and critical minerals. It has been a challenge, he said, to come up with a “white list” of sectors that could be considered safe.
“The red lines have moved back and forth as the nature of technology has changed,” Mr. Pillsbury said.
He added that while Mr. Trump is eager to announce a $1 trillion Chinese investment pledge, he is mindful not to incite political backlash.
“I think there’s been an effort by the administration to avoid getting into a fight with the China hawks,” Mr. Pillsbury added.
Ahead of Mr. Trump’s trip to China, a White House official downplayed the idea that the administration was seeking to create a new $1 trillion Chinese investment program. The White House continues to be focused on pushing China to increase its purchases of American farm goods, which it boycotted for much of last year when trade tensions flared.
Despite the anticipation of a Chinese investment pledge, the details and follow-through will be important.
While Mr. Trump has said that foreign investments have topped $20 trillion, according to the White House’s own investment tracker, U.S. and foreign investment pledges made during Mr. Trump’s second term total $10.6 trillion. Foreign leaders appear to have learned that they can win favor with Mr. Trump by promising whopping investment pledges that they might not fulfill.
“The devil is in the details,” said Philip Ludvigson, a partner in King & Spalding who specializes in national security risks and foreign investment, “about not only where the investment goes but also whether it happens at all.”
Business
‘Cheaper’ funeral option left Somerset man unable to say goodbye
Ed Cullen says his mum had an unattended cremation which saved money but was “devastating” for him.
Source link
Business
Trump brought top CEOs to Beijing but few big deals emerge
There were plenty of choreographed ceremonies but no sweeping trade breakthrough as Trump met Xi in Beijing.
Source link
-
Tech1 week agoA new frontier: Identity stack evolves for agentic systems | Computer Weekly
-
Tech7 days ago‘Orbs,’ ‘Saucers,’ and ‘Flashes’ on the Moon: Pentagon Drops New UFO Files
-
Fashion7 days agoNew orders in German manufacturing up 5% MoM in Mar 2026: Destatis
-
Tech7 days agoNick Bostrom Has a Plan for Humanity’s ‘Big Retirement’
-
Tech1 week agoWhat Microsoft Executives Really Thought About OpenAI in 2018
-
Sports7 days agoShaheen Afridi achieves landmark feat during opening Test against Bangladesh
-
Fashion7 days agoUS’ Carter’s taps retail veteran Sharon Price John as new CEO
-
Entertainment7 days agoRihanna embraces new tattoo given by children
